Save the Date for a presentation and discussion about a new clinical trial studying tovorafenib in hairy cell leukemia (HCL). Tovorafenib is a drug used to treat pediatric cancer that is being studied in other types of cancer, including HCL. Tovorafenib blocks certain proteins made by the mutated BRAF gene. The BRAF mutation is found in over 90% of classic hairy cell cases.

On November 19th, Dr. Seema Bhat from the Ohio State University, the researcher leading the trial, will discuss the study’s objectives and desired outcomes, and answer questions from patients.

Registration will open soon!